Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Biodistribution Stories

2014-04-03 10:05:03

Researchers have discovered that microscopic "bubbles" developed at Kansas State University are safe and effective storage lockers for harmful isotopes that emit ionizing radiation for treating tumors. The findings can benefit patient health and advance radiation therapy used to treat cancer and other diseases, said John M. Tomich, a professor of biochemistry and molecular biophysics who is affiliated with the university's Johnson Cancer Research Center. Tomich conducted the study with...

2013-10-11 23:01:17

Molecular Imaging, a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, announces a new white paper to examine new imaging strategies that can facilitate the discovery and clinical use of new therapeutics and diagnostics. Ann Arbor, MI (PRWEB) October 11, 2013 Molecular Imaging, Inc., in collaboration with Cambridge Healthtech Associates™, held a webinar, which took place on September 10,...

2013-09-05 23:23:13

Molecular Imaging, a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, is sponsoring a webinar to examine new imaging strategies that can facilitate the discovery and clinical use of new therapeutics and diagnostics. Ann Arbor, MI (PRWEB) September 05, 2013 The free webinar, which will take place on September 10, 2013 at 11am ET, will feature presentations by Patrick McConville, Chief...

2012-10-04 10:23:52

ANN ARBOR, Mich., Oct. 4, 2012 /PRNewswire/ -- Molecular Imaging, Inc. has expanded its preclinical nuclear medicine program with the addition of Single Photon Emission Computed Tomography (SPECT) imaging. This decision was driven by the growing industry understanding of the value of in vivo molecular imaging throughout the entire drug development process. SPECT is an exciting preclinical modality that allows researchers to 'tag' potential treatments with a variety of radioactive labels to...

2009-12-14 15:57:51

Nanoparticle could allow diagnosis, treatment in one visit Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat. The all-in-one particle is one of the first examples from a growing field called "theranostics" that develops technologies physicians can use to diagnose and treat diseases in a single procedure. The...

2009-06-15 11:24:36

Fully integrated PET/MRI system could advance research, say researchers at SNM's 56th Annual MeetingA  new PET/MR imaging system has been developed that can successfully provide whole-body images of rats and other small animals, according to researchers at SNM's 56th Annual Meeting in Toronto. The new system could greatly improve imaging capabilities and advance research in many areas."Our system shows great promise because it is able to simultaneously provide the complementary strengths...

2008-11-13 15:00:29

BioReliance Corporation announced today that Dr. Sarah Sheridan, a Scientific Director in BioReliance's Glasgow, Scotland, facility, will deliver a poster presentation regarding her work in gene therapy biodistribution studies at the 16th Annual European Society of Gene and Cell Therapy conference to be held from November 13-16, 2008 in Bruges, Belgium. BioReliance is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and...

2008-08-13 18:00:14

By Anonymous Hooker et al. from the University of California-Berkeley reported on April 25 ahead of print in Molecular Imaging and Biology on a modular synthetic strategy to append imaging agents to a viral capsid. The researchers labeled the inside surface of the hollow protein shell of bacteriophage MS2 (mtMS2) with ^sup 18^F- fluorobenzaldehyde through a multistep bioconjugation strategy. An aldehyde functional group was first attached to interior tyrosine residues through a diazonium...

2008-07-24 12:01:22

QuantRx Biomedical has announced that the company's FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. The Phase I trial was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a positron emission tomography (PET) imaging...

2008-07-23 12:01:24

BOSTON, July 23 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging. BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a PET imaging agent, designed to assess the blood flow in the heart (myocardial perfusion). Myocardial...